Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heike Wulff

Showing results (1-10 of 222) with videos related to

Pageof 23
Sort By:
Expert Opinion on Therapeutic Patents|October 20, 2010
Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840Heike Wulff
ACS Chemical Biology|July 23, 2008
New light on the "old" chloride channel blocker DIDSHeike Wulff
Thorax|April 9, 2013
Ion channelsPeter Bradding, Heike Wulff
Channels (Austin, Tex.)|July 29, 2015
Pharmacological gating modulation of small- and intermediate-conductance Ca(2+)-activated K(+) channels (KCa2.x and KCa3.1)Palle Christophersen, Heike Wulff
Drug Development Research|January 14, 2012
The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for ImmunosuppressionJenny Lam, Heike Wulff
Journal of Cardiovascular Pharmacology|October 31, 2012
Endothelial small-conductance and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targetsHeike Wulff, Ralf Köhler
Current Opinion in Drug Discovery & Development|July 31, 2007
Targeting effector memory T-cells with Kv1.3 blockersHeike Wulff, Michael Pennington
Channels (Austin, Tex.)|December 10, 2015
Recent developments in ion channel pharmacologyHeike Wulff, Palle Christophersen
British Journal of Pharmacology|August 18, 2009
The K+ channels K(Ca)3.1 and K(v)1.3 as novel targets for asthma therapyPeter Bradding, Heike Wulff
Chemical Reviews|May 15, 2008
K+ channel modulators for the treatment of neurological disorders and autoimmune diseasesHeike Wulff, Boris S Zhorov
Pageof 23

Showing results (1-10 of 222) with videos related to

Sort By:
Pageof 23
Expert Opinion on Therapeutic Patents|October 20, 2010
Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840Heike Wulff
ACS Chemical Biology|July 23, 2008
New light on the "old" chloride channel blocker DIDSHeike Wulff
Thorax|April 9, 2013
Ion channelsPeter Bradding, Heike Wulff
Channels (Austin, Tex.)|July 29, 2015
Pharmacological gating modulation of small- and intermediate-conductance Ca(2+)-activated K(+) channels (KCa2.x and KCa3.1)Palle Christophersen, Heike Wulff
Drug Development Research|January 14, 2012
The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for ImmunosuppressionJenny Lam, Heike Wulff
Journal of Cardiovascular Pharmacology|October 31, 2012
Endothelial small-conductance and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targetsHeike Wulff, Ralf Köhler
Current Opinion in Drug Discovery & Development|July 31, 2007
Targeting effector memory T-cells with Kv1.3 blockersHeike Wulff, Michael Pennington
Channels (Austin, Tex.)|December 10, 2015
Recent developments in ion channel pharmacologyHeike Wulff, Palle Christophersen
British Journal of Pharmacology|August 18, 2009
The K+ channels K(Ca)3.1 and K(v)1.3 as novel targets for asthma therapyPeter Bradding, Heike Wulff
Chemical Reviews|May 15, 2008
K+ channel modulators for the treatment of neurological disorders and autoimmune diseasesHeike Wulff, Boris S Zhorov
Pageof 23